2023 World Conference on Lung Cancer (Posters)-EP02.01. Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer

EP02.01. Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer - PDF(Slides)

Pdf Summary

A study conducted by Daniel Kottmann at the University of Cambridge has identified novel therapeutic vulnerabilities in squamous cell lung cancer (LUSC) that are dependent on the SOX2 gene. While most targetable alterations are not present in LUSC, the study found that many LUSC patients exhibit SOX2 gene amplification, which serves as a driver of the disease.<br /><br />The study utilized differential gene expression analysis (DEA) and highlighted NTRK2 as being overexpressed in SOX2-high LUSC tumors. Additionally, it found that NTRK2 is a vulnerability in squamous cell lines of lung cancer. Depletion of NTRK2 in these cell lines led to a reduction in cell viability.<br /><br />Truncated isoforms of the TrkB protein were found to be the dominant isoforms in LUSC. Despite lacking certain functional domains, these isoforms are still involved in cancer signaling pathways. The study also revealed that T1 isoforms of TrkB were prevalent in cancer and played a role in cancer signaling.<br /><br />Based on these findings, the study suggests that TrkB may be a novel therapeutic vulnerability in SOX2-driven LUSC. Targeting NTRK2 and TrkB could potentially lead to new treatment strategies for these types of lung cancer.<br /><br />Overall, this study provides valuable insights into the mechanisms and vulnerabilities of SOX2-dependent squamous cell lung cancer, highlighting potential targets for therapeutic intervention.

Asset Subtitle

Daniel Kottmann

Meta Tag

Speaker Daniel Kottmann

Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets

Keywords

squamous cell lung cancer

LUSC

SOX2 gene

NTRK2

differential gene expression analysis

cell viability

TrkB protein

cancer signaling pathways

therapeutic vulnerability

new treatment strategies